Head-to-head · WeighScore
LaSara Medical Group vs Zealthy
The verdict
LaSara Medical Group takes it — 54.5/100 to 46.7/100.
LaSara Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LaSara Medical Group is a national telehealth provider with in-person availability in southern California, offering compounded semaglutide and tirzepatide alongside a broader menu of TRT, NAD+, sermorelin, B12, and enclomiphene — a multi-modality clinic rather than a pure GLP-1 platform.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | LaSara Medical Group | Zealthy |
|---|---|---|
| WeighScore | 54.5/100 | 46.7/100 |
| Grade | C | C |
| Site position | #505 | #539 |
| Semaglutide | $289/mo (compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $399/mo (bundle, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Site position #505 · C
Strengths
- Multi-modality clinic — compounded GLP-1s alongside TRT, peptides, B12, NAD+, sermorelin, and enclomiphene
- National telehealth plus an in-person option in Southern California — uncommon hybrid model
- Free initial consultation
- Active promotional pricing (30% off sitewide at the time of review)
- GLP-1 pricing now published on product pages: compounded semaglutide from $233/mo, tirzepatide from $325/mo on annual bundles
Where it loses points
- Legal entity name and state of incorporation not disclosed
- Compounding pharmacy partner not named
- LegitScript certification status not confirmed
- Per-state availability not listed despite the national-telehealth claim
- Lab work and ongoing monitoring inclusion not clearly disclosed for the multi-modality menu
Site position #539 · C
FDAWarning letter issued to FitRX, LLC dba Zealthy in September 2025. See the FDA warning-letter database.
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued FitRX, LLC dba Zealthy a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.